Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 1.00 |
| ▸ | TAS2R31 | P59538 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 5/20 | 0.82 |
| ▸ | POLB | P06746 | 5/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | NPC1 | O15118 | 3/20 | 0.82 |
| ▸ | GFER | P55789 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.82 |
| ▸ | RECQL | P46063 | 2/20 | 0.82 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | CASP6 | P55212 | 1/20 | 0.82 |
| ▸ | FLT3 | P36888 | 4/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | GABRP | O00591 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jaceosidine SCHEMBL29926544 | 1.00 | HSD17B2 (1.00) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| Eupatilin SCHEMBL29926197 | 0.93 | HDAC6 (1.00) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| Eupatilin SCHEMBL29568655 | 0.93 | HDAC6 (1.00) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| Cirsileneol SCHEMBL2045672 | 0.93 | HSD17B2 (0.86) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| Eupatilin SCHEMBL1033509 | 0.93 | HDAC6 (1.00) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| Cirsileneol SCHEMBL29435128 | 0.93 | HSD17B2 (0.86) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| SCHEMBL30799172 | 0.90 | FLT3 (0.86) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| SCHEMBL8069022 | 0.90 | FLT3 (0.86) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| SCHEMBL6239788 | 0.90 | HSD17B2 (0.82) | HSD17B2TAS2R31HDAC6MEN1POLB | |
| SCHEMBL29906158 | 0.90 | HSD17B2 (0.82) | HSD17B2TAS2R31HDAC6MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20250127199-A1 | COMPOSITION COMPRISING A NUTRIENT AND A TASTE MODULATOR | FIRMENICH SA (CH) | 2025-04-24 | — | — | US | claimed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | claimed |
| CN-116459287-B | Application of lindley eupatorium herb ethanol extract and flavone part thereof in preparation of medicines for preventing or treating ulcerative colitis | 苏州大学 | 2025-03-21 | — | — | CN | claimed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-4384027-A1 | COMPOSITION COMPRISING A NUTRIENT AND A TASTE MODULATOR | Firmenich SA (CH) | 2024-06-19 | — | — | EP | claimed |
| CN-118108692-A | Method for rapidly extracting and separating eupatilin and brown cyanidin from north mugwort | 安阳工学院 | 2024-05-31 | — | — | CN | claimed |
| US-20240099344-A1 | HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE | FIRMENICH SA (CH) | 2024-03-28 | — | — | US | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| CN-107854507-B | Method for extracting flavonoid component from folium artemisiae argyi | 山东省中医药研究院 | 2021-01-22 | — | — | CN | claimed |
| CN-108113985-B | Application of eupatorium lindleyanum flavone part in preparation of anti-hepatitis B virus medicines | 苏州大学 | 2020-07-21 | — | — | CN | claimed |
| CN-110824047-A | Method for judging fluff beating proportion of folium artemisiae argyi | 天津中医药大学 | 2020-02-21 | — | — | CN | claimed |
| CN-107854692-B | Pharmaceutical composition for treating lipopexia and application thereof | 延边大学 | 2019-12-31 | — | — | CN | claimed |
| EP-3421035-A1 | NOVEL USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING FIBROSIS BY USING EPITHELIAL-MESENCHYMAL TRANSITION INHIBITORY ACTIVITY THEREOF | Osteoneurogen Inc. (KR) | 2019-01-02 | — | — | EP | claimed |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | claimed |
| CN-106306395-A | Sweet potato residue feed and preparation method thereof | 自然味（重庆）农业科技股份有限公司 | 2017-01-11 | — | — | CN | claimed |
| WO-2006004358-A1 | DICOUMAROL-REMOVED EXTRACT OF ARTEMISIA, PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | DONG-A PHARM. CO., LTD. (KR) | 2006-01-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | HSD17B2 220/4885TAS2R31 4176/4885HDAC6 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.